Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer.

Item

http://www.wikidata.org/entity/Q36145737

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Evaluation of the Survival Ben ...... Triple-Negative Breast Cancer.

@ast

Evaluation of the Survival Ben ...... Triple-Negative Breast Cancer.

@en

type

Item

label

Evaluation of the Survival Ben ...... Triple-Negative Breast Cancer.

@ast

Evaluation of the Survival Ben ...... Triple-Negative Breast Cancer.

@en

prefLabel

Evaluation of the Survival Ben ...... Triple-Negative Breast Cancer.

@ast

Evaluation of the Survival Ben ...... Triple-Negative Breast Cancer.

@en

P1476

Evaluation of the Survival Ben ...... Triple-Negative Breast Cancer.

@en

P2093

Byung Joo Song

http://www.w3.org/2001/XMLSchema#string

Eun-Kyu Kim

http://www.w3.org/2001/XMLSchema#string

Eunyoung Kang

http://www.w3.org/2001/XMLSchema#string

Hyun-Ah Kim

http://www.w3.org/2001/XMLSchema#string

Korea Breast Cancer Society

http://www.w3.org/2001/XMLSchema#string

Min Hee Hur

http://www.w3.org/2001/XMLSchema#string

Min-Ki Seong

http://www.w3.org/2001/XMLSchema#string

Woo Chul Noh

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

Adjuvant trastuzumab in HER2-positive breast cancer.

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer.

Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.

P304

271-278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4048/JBC.2015.18.3.271

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Seho Park

P577

2015-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282910934

http://www.w3.org/2001/XMLSchema#string

P698

26472978

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

4600692

http://www.w3.org/2001/XMLSchema#string